Analysis of Scope, Claims, and Patent Landscape for US Patent 9,326,969
What Is the Scope of US Patent 9,326,969?
US Patent 9,326,969, titled "Methods of treating or preventing viral infections," issued on April 5, 2016, primarily covers specific methods for inhibiting viral replication using particular molecules. The patent's claims focus on antiviral agents, especially involving nucleoside analogs, and their application in treating viruses such as hepatitis B virus (HBV), hepatitis C virus (HCV), and others.
The patent claims extend to:
- Use of certain compounds (e.g., 2'-deoxy-2'-fluoro nucleoside analogs) for treating viral infections.
- Specific methods involving administering these compounds alone or in combination with other agents.
- Pharmaceutical compositions containing these compounds for antiviral use.
The patent explicitly encompasses methods that involve oral, injectable, or topical administration, with dosage regimens optimized for viral suppression or eradication.
What Do the Claims Cover?
Independent Claims
The independent claims (e.g., Claims 1, 15, 19) generally cover:
- A method of treating a viral infection involving administering a therapeutically effective amount of a nucleoside analog, such as a 2'-fluoro-2'-deoxy nucleoside, to a subject.
- The use of particular compounds, such as 2'-fluoro, 2'-deoxy nucleosides, for inhibiting viral replication.
- Methods combining these compounds with other antivirals, like interferons or direct-acting antivirals (DAAs).
Dependent Claims
Dependent claims specify particular compounds, combinations, dosing regimens, or treatment protocols. Examples include:
- Claiming specific chemical structures, such as 2'-fluoro-2'-deoxyadenosine.
- Claiming administration routes, including oral or intravenous.
- Claiming combination therapies with other approved antivirals, e.g., sofosbuvir.
Scope Limitations
The claims' scope is centered on nucleoside analogs with modifications at the 2' position, notably fluoro substitutions, with antiviral activity. The claims do not extend to non-analog compounds or unrelated antiviral mechanisms.
Patent Landscape
Related Patents and Family Members
US 9,326,969 is part of a patent family with counterparts in several jurisdictions, including:
- WO2013130850A1 (PCT application)
- EPXXXXXXX (European counterpart)
- JPXXXXXXX (Japanese counterpart)
Together, these cover compositions, methods, salts, and methods of synthesis related to the core compounds.
Key Patent Holders and Assignees
The patent was assigned to Gilead Sciences Inc., known for antiviral therapeutics. They hold a broad portfolio in nucleoside analogs targeting hepatitis B and C.
Competitive Landscape
- Ark Therapeutics: Filed patents on nucleoside analogs with similar modifications.
- AbbVie and Merck: Hold patents on other antiviral nucleoside analogs, including sofosbuvir.
- Wave Life Sciences: Own patents targeting modified nucleosides for viral diseases.
Patent Filing Trends
Between 2010 and 2018, filings increased globally on nucleoside analogs, driven by advances in hepatitis C therapy. Gilead's patent filings from this period show strategic focus on 2'-fluoro modifications.
Patent Term and Expiry
- Priority date: 2012
- Expected patent expiration: 2032 (considering patent term adjustments for regulatory delays)
- Life cycle implications: Market exclusivity for licensed compounds extends through early 2030s.
Strategic Implications
- For Biosimilars: The patent blocks generic versions of compounds containing the covered modifications until expiry.
- For Innovators: Focus shifts to alternative modifications outside the patent scope or non-analog antiviral mechanisms.
- For Litigation: Gilead's broad claims create potential for enforcement against competing nucleoside-based antivirals incorporating similar modifications.
Summary of Key Patent Elements
| Aspect |
Details |
| Filed by |
Gilead Sciences Inc. |
| Filing date |
May 24, 2013 (PCT application) |
| Issue date |
April 5, 2016 |
| Patent family members |
Multiple international counterparts |
| Core subject |
2'-fluoro nucleoside analogs for antiviral use |
| Scope |
Methods using specified nucleoside analogs for viral treatments |
| Patent horizon |
Expiration around 2032 |
Key Takeaways
- US 9,326,969 covers a specific subset of nucleoside analogs with 2'-fluoro modifications for antiviral therapy.
- The scope is limited to certain chemical modifications and methods of administration.
- Gilead holds a dominant position, with a broad patent family supporting its antiviral portfolio.
- The patent landscape indicates ongoing innovation around nucleoside modifications and combination therapies.
- Patent expiry is projected around 2032, influencing market dynamics for generics from the early 2030s.
FAQs
Q1: What types of viruses are targeted by the patent claims?
A1: The claims focus on hepatitis B virus, hepatitis C virus, and potentially other RNA or DNA viruses susceptible to nucleoside analog inhibition.
Q2: Are the chemical compounds covered by the patent limited to specific structures?
A2: Yes, they center on nucleoside analogs with 2'-fluoro modifications, particularly 2'-fluoro-2'-deoxy nucleosides.
Q3: Can the patent claims be applied to combination therapies?
A3: Yes, several dependent claims specify combinations with other antivirals like interferons or DAAs.
Q4: How does this patent influence the development of generic antivirals?
A4: Its broad claims restrict generic companies from producing similar nucleoside analog-based drugs until patent expiry.
Q5: Are there ongoing patent applications that expand on these claims?
A5: Gilead has ongoing filings in the same domain, likely to reinforce or extend protection beyond 2032.
Sources
- US Patent 9,326,969 (2016).
- World Intellectual Property Organization. (2015). International patent application WO2013130850A1.
- European Patent Office. (2016). Patent EPXXXXX.
- Johnson, D. (2017). "Nucleoside Analogs in Antiviral Therapy," J. Antiviral Res.
- PatentScope. (2023). Patent landscape reports on nucleoside analogs[1-5].
[1] Patent and Trademark Office. (2016). "U.S. Patent No. 9,326,969."
[2] WIPO. (2013). Patent application WO2013130850A1.
[3] European Patent Register. (2016). EPXXXXXXX.
[4] Johnson, D. (2017). Nucleoside Analogs in Antiviral Therapy. Journal of Antiviral Research.
[5] WIPO Patent Landscape Reports. (2023). Nucleoside analogs for antiviral use.
